Panovir（EPCLUSA）is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection:
1.without cirrhosis or with compensated cirrhosis
2.with decompensated cirrhosis for use in combination with ribavirin
DOSAGE AND ADMINISTRATION
1. Testing Prior to the Initiation of Therapy: Test all patients for HBV infection by measuring HBsAg and anti-HBc.
2. Recommended dosage: One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily with or without food
3. See recommended treatment regimen and duration in patients with genotypes 1, 2, 3, 4, 5, or 6 HCV in table below:
Panovir’s brand name is EPCLUSA®by Gilead. Panovir is a fixed-dose combination of sofosbuvir from Incepta Pharmaceuticals, which is one of the pharmaceutical company in Bangladesh.
For more Prescribing information，please check the → “FDA Prescribing Information”.